FDA Takes Action Against 14 Companies Selling Illegal Cancer Treatments
FDA posted warning letters to 14 US-based companies yesterday, addressing the illegal selling over 65 products that falsely claim to prevent, diagnose, treat, or cure cancer. These products are contained on websites and social media, and are marketed and sold without FDA approval.
The FDA requested responses from each company to affirm how each will correct the violations. Failure to correct the violations in a timely manner may result in legal action, including product seizure, injunction, and/or criminal prosecution.
The illegally sold products cited in the warning letters posted include a variety of product types, such as pills, topical creams, ointments, oils, drops, syrups, teas, and diagnostics (such as thermography devices). They include products marketed for use by humans or pets that make illegal, unproven claims regarding preventing, reversing, or curing cancer; killing/inhibiting cancer cells or tumors; or other similar anti-cancer claims.
The FDA encourages health care professionals and consumers to report adverse reactions associated with these or similar products to the agency’s MedWatch program.
FDA Issues Refusal to File for ImmunityBio’s sBLA for Anktiva in BCG-Unresponsive NMIBC
May 6th 2025The Refusal to File letter comes despite the FDA’s prior encouragement to submit a supplemental biologics license application for Anktiva in patients with BCG-unresponsive non-muscle invasive bladder cancer with papillary disease.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
